6271-05-2

Basic information

• Product Name: N-(2-methoxyphenyl)-4-methylpiperazine-1-carboxamide
• CAS NO: 6271-05-2
• Molecular Formula: C₁₃H₁₉N₃O₂
• Molecular Weight: 249.3089
• Mol File: 6271-05-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 435.7°C at 760 mmHg
• Flash Point: 217.3°C
• Density: 1.18g/cm³
• Vapor Pressure: 8.55E-08mmHg at 25°C
• Refractive Index: 1.584
• CAS DataBase Reference: N-(2-methoxyphenyl)-4-methylpiperazine-1-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-methoxyphenyl)-4-methylpiperazine-1-carboxamide(6271-05-2)
• EPA Substance Registry System: N-(2-methoxyphenyl)-4-methylpiperazine-1-carboxamide(6271-05-2)

Safety Data

• Hazardous Substances Data: 6271-05-2(Hazardous Substances Data)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 700-87-8 1-Isocyanato-2-methoxy-benzene 

Relevant articles and documents

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, de? formations and chromosomal abnormalities.